Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Etoposide in Treating Young Patients With Relapsed Ependymoma

Phase 2

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2006-01-18

Last Posted Date: 2013-08-07

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 14

Registration Number: NCT00278252

Locations: 🇬🇧
Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom

Combination Chemotherapy Followed By Surgery With or Without Radiation Therapy in Treating Young Patients With Stage II or Stage III Neuroblastoma

Phase 3

Conditions: Neuroblastoma

First Posted Date: 2006-01-13

Last Posted Date: 2013-09-17

Lead Sponsor: Children's Cancer and Leukaemia Group

Registration Number: NCT00276731

Locations: 🇬🇧
Institute of Child Health at University of Bristol, Bristol, England, United Kingdom
🇬🇧
Royal London Hospital, London, England, United Kingdom
🇬🇧
Sir James Spence Institute of Child Health, Newcastle-Upon-Tyne, England, United Kingdom

and more 18 locations

Etoposide, Carboplatin, and Bleomycin in Treating Young Patients Undergoing Surgery For Malignant Germ Cell Tumors

Not Applicable

Conditions: Brain and Central Nervous System Tumors
Childhood Germ Cell Tumor
Extragonadal Germ Cell Tumor
Ovarian Cancer

First Posted Date: 2006-01-13

Last Posted Date: 2013-09-17

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 100

Registration Number: NCT00276718

Locations: 🇮🇪
Our Lady's Hospital for Sick Children, Dublin, Ireland
🇬🇧
Great Ormond Street Hospital for Children NHS Trust, London, England, United Kingdom
🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom

and more 18 locations

Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

First Posted Date: 2006-01-13

Last Posted Date: 2016-09-26

Lead Sponsor: German CLL Study Group

Target Recruit Count: 30

Registration Number: NCT00276809

Locations: 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
🇩🇪
Universitatsklinikum Heidelberg, Heidelberg, Germany
🇩🇪
University Hospital Schleswig-Holstein - Kiel Campus, Kiel, Germany

and more 9 locations

Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Biological: filgrastim
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: etoposide
Drug: fludarabine phosphate
Drug: melphalan
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2006-01-11

Last Posted Date: 2018-05-11

Lead Sponsor: German CLL Study Group

Target Recruit Count: 169

Registration Number: NCT00275015

Locations: 🇩🇪
Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany
🇩🇪
Robert Roessle Comprehensive Cancer Center at University of Berlin - Charite Campus Buch, Berlin, Germany
🇩🇪
Internistische Praxis - Trier, Trier, Germany

and more 50 locations

Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors

Phase 3

Conditions: Childhood Germ Cell Tumor
Extragonadal Germ Cell Tumor
Ovarian Cancer

First Posted Date: 2006-01-11

Last Posted Date: 2013-09-17

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 105

Registration Number: NCT00274950

Locations: 🇬🇧
Addenbrooke's Hospital, Cambridge, England, United Kingdom
🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom

and more 16 locations

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2006-01-11

Last Posted Date: 2011-02-11

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 40

Registration Number: NCT00274807

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Biological: filgrastim
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: carboplatin
Drug: prednisone
Drug: etoposide
Drug: vincristine
Drug: ifosfamide

First Posted Date: 2006-01-11

Last Posted Date: 2023-06-29

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 100

Registration Number: NCT00274924

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Mason District Hospital, Havana, Illinois, United States
🇺🇸
Greater Baltimore Medical Center Cancer Center, Baltimore, Maryland, United States

and more 99 locations

Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: busulfan
Drug: cyclophosphamide
Drug: etoposide
Drug: melphalan
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2005-12-15

Last Posted Date: 2013-11-20

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 42

Registration Number: NCT00265889

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

HD12 for Advanced Stages

Phase 3

Completed

Conditions: Hodgkin´s Lymphoma

First Posted Date: 2005-12-13

Last Posted Date: 2012-06-25

Lead Sponsor: University of Cologne

Registration Number: NCT00265031

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy